Skip to main content
. 2024 Sep 18;15:7999. doi: 10.1038/s41467-024-51924-3

Table 1.

Clinical characteristics, immunosuppressive treatments and COVID-19 course

ID Age (range) Comorbidities Immunosuppressive medications in the previous 6 months Previous covid vaccine SARS-CoV2 anti-S Ab SARS-CoV2 anti-N Ab Days PCR + Neutropenia ( < 1.42 × 103/ml) Lympho penia ( < 1.17 × 103/ml) Total IgG 610 –1616 mg/dL PNA ICU O2 Covid treatments Covid outcome
Fludarabine/melphalan/ TBI 400 cGy Alemtuzumab Tacrolimus MMF Anti-thymocyte globulin Rituximab Steroids Other RDV DEXA Toci mAb PAX
1995 60–65 MDS, SCT Yes Yes Yes Yes Ruxolitinib No No Yes 28 No Yes 621 Yes No No Yes Yes No No No Discharged home
2646 40–45 AML Yes

Decitabine

Venetoclax

 No No Yes 32+ No No 695 Yes Yes HFNC Yes Yes No No No Discharged home.
10939 80–85 Kidney Tx Yes Yes No No Yes 33‡ No Yes 1072 Yes Yes INV Yes (x2) Yes No No No Deceased
11595 66–70 AIHA, MGUS Yes Yes Ibrutinib No No No 38 Yes Yes 217 Yes No HFNC Yes Yes No No No Deceased
12105 66–70 T-PLL, SCT Yes Yes Yes Yes Yes Yes Yes PLEX No No No 58‡ Yes Yes 232 Yes Yes INV Yes Yes Yes Casi/indi No Deceased
14675 66–70 CLL Yes Yes

Polartuzmab

Etoposide

Doxorubicin

CFX

 Yes No No 66 No Yes 578 Yes No No Yes No No Tixa/Cilga Yes Discharged home
16624 60–65 Mantle cell lymphoma, SCT Yes Yes Yes Yes No 42 No Yes 418 Yes No NC Yes Yes No No No Discharged home
16902 70–75 MDS, SCT Yes Yes Yes Yes No Yes No 50‡ Yes Yes 484 Yes No INV Yes (x2) Yes Yes Sotrovimab No Deceased
16915 20–25 AML, SCT Yes Yes Yes Yes Yes No No No 63 No No 563 Yes No No Yes No No Tixa/Cilga No Discharged home
17062 26–30 BMFS, SCT Yes Yes Yes Yes Fludarabine, CFX No Yes Yes 72 Yes Yes 270 Yes Yes NC Yes Yes No No No Deceased
17320 70–75 Mantle cell lymphoma

Fludarabine, CFX

CAR-T cells

 Yes No No 34 Yes Yes 447 Yes No No Yes Yes No No No Discharged home
17386 60–65 DLBCL Yes Yes CHOP No Yes No 157 No Yes 810 Yes No NC Yes (x4) Yes Yes Sotrovimab No Discharged home
17423 60–65 B-ALL, SCT, GVHD Yes Yes Yes Yes Ruxolitinib Yes Yes No 190 No Yes 797 Yes No NC Yes Yes No No No Deceased
18323 36–70 AML, SCT Yes Yes Yes Yes Desatinib, No No No 131 No Yes 926 Yes No No Yes No No Tixa/Cilga Bebtel Yes Discharged home
17072 60–65 MM Yes Elranatam Yes No No 81 No Yes 441 Yes Yes IMV Yes (x3) Yes No No Yes Deceased

AIHA autoimmune hemolytic anemia, ALL acute lymphoid leukemia, AML acute myeloid leukemia, aSCT autologous stem cell transplant, BMFS bone marrow failure syndrome, CHOP cyclophosphamide, doxorubicin, vincristine, prednisone, CLL chronic Lymphoid Leukemia, DLBCL diffuse large B cell Lymphoma, GVHD graft versus host disease, MDS myelodysplastic syndrome, MGUS monoclonal gammopathy of undetermined significance, MM multiple myeloma, PLEX plasma exchange, SCT stem cell transplant, TBI total body irradiation, T-PLL T-cell prolymphocytic leukemia, Tx transplant, CFX cyclophosphamide, Bebtel Bebtelovimab, Casi/indi casirivimab and imdevimab, DEXA dexamethasone, HFNC high-flow nasal cannula, ICU intensive care unit, IMV invasive mechanical ventilation, NC nasal cannula, NIV non-invasive ventilation, O2 oxygen requirements, PAX nirmatrelvir/ritonavir (PaxlovidTM), PNA pneumonia, RDV remdesivir, Toci Tociluzimab, Tixa/Cilga Tixagevimab/Cilgavimab (EvusheldTM).

‡Indicates that the patient died while SARS-CoV2 positive; +indicates that the patient died in the following month after hospitalization without retesting for SARS-CoV2.